Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies

[ X ]

Tarih

2013

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

W B Saunders Co Ltd

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Objectives: Malignant pleural effusion (MPE) means poor prognosis in the majority of cases. Intrapleural Hyperthermic perfusion chemotherapy (HIPEC) looks promising approach for these patients. We aimed to investigate whether cytoreductive surgery followed by HIPEC provides any survival benefit in cases with metastatic MPEs. Methods: Between January 2009 and December 2011, 19 patients with metastatic MPEs were treated with HIPEC following surgical interventions such as pleurectomy/decortication and/or lung resection (Group 1). Comparison was done with historical control groups consisted of patients who received either talc pleurodesis or pleurectomy/decortication followed by systemic treatment for the management of metastatic MPEs between June 2007 and June 2008 (group 2 and 3). Statistical analyses including overall survival, disease free interval were done for the group comparisons. Results: Median survival in group 1, 2 and 3 were 15.4, 6, 8 months, respectively. One year survival was 54.7% in group 1 where it was 0.6% and 0.8% in group 2 and 3, respectively. There was no operative mortality. Morbidity was occurred in 1 patient in group 1 (5.3%). Conclusions: HIPEC combined with cytoreductive surgery seems to be a promising treatment option for subjects with metastatic MPEs. Further studies are needed for the optimization of HIPEC method, drug of choice, and the best combination therapy for the multimodal treatment. (C) 2013 Elsevier Ltd. All rights reserved.

Açıklama

Anahtar Kelimeler

Malignant Pleural Effusion, Lung Carcinoma, Hyperthermic Perfusion Chemotherapy

Kaynak

Respiratory Medicine

WoS Q Değeri

Q2

Scopus Q Değeri

Q1

Cilt

107

Sayı

5

Künye